Vitiligo: Why White Patches Appear and What Treatment Can Do

What is vitiligo and why does it happen?

Vitiligo is an autoimmune condition in which the body's immune system — specifically CD8+ cytotoxic T cells — identifies and destroys melanocytes, the cells responsible for producing melanin, the pigment that colors skin, hair, and eyes 1Ref 1Chang WL, Lee WR, Kuo YC, Huang YH (2021).Vitiligo: An Autoimmune Skin Disease and its Immunomodulatory Therapeutic Intervention.Vitiligo pathophysiology: CD8+ T-cell-mediated melanocyte destruction via JAK-STAT signaling pathway. Without functioning melanocytes, the affected skin turns chalky white.

The underlying immune attack travels through the JAK-STAT signaling pathway, which has become a central target for newer treatments 1Ref 1Chang WL, Lee WR, Kuo YC, Huang YH (2021).Vitiligo: An Autoimmune Skin Disease and its Immunomodulatory Therapeutic Intervention.Vitiligo pathophysiology: CD8+ T-cell-mediated melanocyte destruction via JAK-STAT signaling pathway. Genetic predisposition, oxidative stress in the skin, and possibly trauma or friction (the Koebner phenomenon — new patches appearing where skin has been injured) all contribute to when and where vitiligo develops.

Vitiligo affects people of every skin tone and ethnicity. A 2024 global systematic review and modelling study estimated the worldwide lifetime prevalence at roughly 0.36% of the general population 2Ref 2Akl J, Lee S, Ju HJ, et al. (Global Vitiligo Atlas GLOVA) (2024).Estimating the burden of vitiligo: a systematic review and modelling study.Global lifetime prevalence of vitiligo estimated at approximately 0.36% of the general population. Patches tend to be more visually prominent on darker skin, and the psychosocial burden can be correspondingly greater in those populations.

How is vitiligo different from other causes of lighter skin?

Not every light patch is vitiligo. The distinguishing features matter because different conditions need different care.

Pityriasis alba — common in children and young adults, especially those with eczema. Patches are slightly lighter than surrounding skin (not chalk-white), mildly scaly, and tend to fade on their own. Usually on the face and arms.

Tinea versicolor — a yeast overgrowth on the skin that temporarily disrupts pigment. Patches are tan, pink, or lighter than surrounding skin with a fine scale; mostly on the trunk and upper arms; becomes more noticeable after sun exposure. Responds to antifungal treatment.

Post-inflammatory hypopigmentation — lighter skin where a rash, eczema, wound, or burn healed. Color is reduced but not fully absent, and there is a clear prior event at that location. Usually temporary.

Chemical leukoderma — true loss of pigment at sites of repeated contact with specific chemicals (rubber gloves, certain hair dyes, industrial compounds). Can look like vitiligo but has a contact-exposure history.

Vitiligo patches are typically chalk-white (fully depigmented, not merely lighter), sharply bordered, and grow over time. A Wood's lamp — an ultraviolet light used during a skin exam — makes vitiligo patches fluoresce brightly white, helping distinguish them from other conditions.

What are the types of vitiligo, and why does the type matter?

The type of vitiligo a person has shapes both how the condition behaves and which treatments tend to work best.

• Generalized (non-segmental) vitiligo: The most common form. Patches appear on both sides of the body, often roughly symmetrically, and tend to spread gradually over time. This is the autoimmune form and the one studied in most treatment trials.
• Segmental vitiligo: Patches appear on one side or segment of the body, progress for a limited period, and then typically stabilize. Less strongly associated with other autoimmune conditions. Often responds to treatment differently.
• Focal vitiligo: One or a small number of localized patches that remain stable.
• Universal vitiligo: Extensive depigmentation covering most of the body.

Whether vitiligo is active (spreading) or stable (unchanged for months or years) is equally important — active disease may warrant earlier or more aggressive intervention, and some surgical options are reserved specifically for long-term stable disease.

What treatments are available for vitiligo now?

Vitiligo treatment has two objectives: stopping further spread and restoring pigment. Repigmentation is partial in many cases, and no treatment is universally effective. A dermatologist will recommend options based on the type, activity, extent, and location of vitiligo, as well as individual preferences 3Ref 3Retamal C, Hartmann D, Valenzuela F (2025).Vitiligo: A Review of Pathogenesis and Treatments, Including New Therapies on the Horizon.Overview of vitiligo treatment approaches and emerging therapies including JAK inhibitors.

Topical corticosteroids — a long-established first-line approach for localized patches. They reduce immune activity locally, allowing surviving melanocyte populations to recover. Careful use is important to avoid skin thinning, especially on the face.

Topical calcineurin inhibitors (tacrolimus, pimecrolimus) — non-steroid immune modulators often preferred for sensitive areas such as the face, neck, and genitals.

Ruxolitinib cream (Opzelura) 1.5% — as of July 2022, the first and only FDA-approved topical medication specifically indicated for non-segmental vitiligo in adults and adolescents 12 and older. It works by inhibiting JAK1 and JAK2 enzymes in the pathway driving the autoimmune attack on melanocytes. In the TRuE-V phase 3 trials — two randomized, controlled studies enrolling 674 patients — approximately 30% of patients applying ruxolitinib cream twice daily achieved 75% improvement in facial repigmentation at 24 weeks, compared with roughly 7–11% on vehicle; efficacy continued to improve through week 52 4Ref 4Rosmarin D, Passeron T, Pandya AG, Grimes P, Harris JE, Desai SR, Lebwohl M, Ruer-Mulard M, Seneschal J, Wolkerstorfer A, Kornacki D, Sun K, Butler K, Ezzedine K; TRuE-V Study Group (2022).Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo.TRuE-V phase 3 trials: ruxolitinib 1.5% cream achieved F-VASI75 in ~30% of patients at week 24 vs ~7-11% on vehicle; FDA-approved July 2022 for non-segmental vitiligo ages 12+.

Narrowband UVB (NB-UVB) phototherapy — a specialized light treatment delivered in a dermatology clinic or, in some cases, with a home device prescribed by a dermatologist. It stimulates surviving melanocytes and suppresses local immune activity. The Vitiligo Working Group published evidence-based recommendations for NB-UVB use in 2017 5Ref 5Mohammad TF, Al-Jamal M, Hamzavi IH, Harris JE, Leone G, Cabrera R, Lim HW, Pandya AG, Esmat SM (2017).The Vitiligo Working Group recommendations for narrowband ultraviolet B light phototherapy treatment of vitiligo.Evidence-based recommendations for NB-UVB phototherapy in vitiligo; face and neck lesions respond better than extremity lesions. Face and neck lesions respond better than extremity lesions. Multiple sessions — often two to three per week over months — are typically required.

Excimer laser — targeted UVB for smaller, localized patches; the same mechanism as NB-UVB but focused on a specific area.

Oral JAK inhibitors — newer systemic medications in the same drug class; evidence is accumulating in clinical trials for extensive or rapidly spreading vitiligo that has not responded to topical approaches 6Ref 6Sallehuddin N, Md Fadilah NI, Fauzi MB, Maarof M (2025).A Scoping Review of Pathogenesis, Current Treatments, and Novel Approaches for Vitiligo.Overview of oral JAK inhibitors and emerging systemic treatments for extensive vitiligo.

Surgical repigmentation — for stable vitiligo that has not responded to medical treatment; involves transplanting melanocytes or small skin grafts from unaffected areas. Reserved for carefully selected cases.

Sun protection and cosmetic options — depigmented skin has no melanin to absorb UV radiation, making it far more susceptible to sunburn. Broad-spectrum sunscreen on affected areas is consistently recommended. For those who prefer not to pursue medical treatment, specialized cosmetic cover products and self-tanners formulated for vitiligo are available.

What other health conditions are associated with vitiligo?

Vitiligo is an autoimmune condition, and autoimmune conditions often travel together. The most important association is with autoimmune thyroid disease — including Hashimoto's thyroiditis and Graves' disease. A systematic review and meta-analysis of 77 studies found that thyroid disorders are consistently more prevalent in people with vitiligo than in the general population 7Ref 7Yuan J, Sun C, Jiang S, Lu Y, Zhang Y, Gao XH, Wu Y, Chen HD (2019).The Prevalence of Thyroid Disorders in Patients With Vitiligo: A Systematic Review and Meta-Analysis.Thyroid disorders (including Hashimoto's thyroiditis) are significantly more prevalent in vitiligo patients than in the general population; meta-analysis of 77 studies. Because thyroid disease can be clinically silent for years, dermatologists commonly recommend thyroid function screening (TSH, thyroid antibodies) at diagnosis.

Other autoimmune conditions that occur at higher rates in people with vitiligo include type 1 diabetes, alopecia areata, rheumatoid arthritis, and lupus. A clinician may ask about personal and family history of these conditions and consider targeted screening when symptoms suggest them.

How does vitiligo affect quality of life?

Vitiligo is a skin condition, but its impact is routinely much broader. A systematic literature review of 168 studies found that depression and anxiety are among the most commonly reported psychosocial comorbidities in people with vitiligo — depression was identified across 41 studies with prevalence ranging widely, and anxiety across 20 studies 8Ref 8Ezzedine K, Eleftheriadou V, Jones H, Bibeau K, Kuo FI, Sturm D, Pandya AG (2021).Psychosocial Effects of Vitiligo: A Systematic Literature Review.Depression and anxiety are the most commonly reported psychosocial comorbidities in vitiligo; 168 studies analyzed; stigmatization, avoidance, and sleep disturbance also documented. Stigmatization, avoidance behavior, sexual difficulties, and sleep disturbance were also commonly reported.

The psychosocial burden tends to be greater when patches are on visible areas (face, hands), in people with darker skin tones where color contrast is most prominent, and in younger patients. These experiences are real and clinically meaningful — not secondary to the physical condition. A care plan that addresses appearance-related distress alongside the skin condition is appropriate and available. Dermatologists with experience in psychodermatology, mental health referrals, and vitiligo patient communities can all be part of that support.

What to bring to a dermatology visit

Coming prepared helps a clinician confirm the diagnosis, assess activity, and discuss realistic options.

• Clear photos of the patches in natural light from multiple angles, plus older photos to show how they have changed over time
• An approximate timeline of when patches first appeared and whether they have been growing, stable, or spreading rapidly
• A list of any personal or family history of autoimmune conditions (thyroid disease, type 1 diabetes, alopecia areata, lupus)
• Any products — cosmetics, rubber items, industrial chemicals — that have been in regular contact with affected skin
• A list of current medications and supplements
• A sense of how much the vitiligo is affecting daily life and self-image, since this genuinely shapes treatment conversations

Useful questions to raise: What type of vitiligo do I have, and is it active or stable? Which treatment would you start with for my pattern and skin tone? How long before I might see results? Do I need bloodwork to check for related autoimmune conditions? Is phototherapy an option, and can it be done at home?